Research & advocacy
We work toward more equitable pancreatic cancer care in Canada, with a focus on four priorities: national care pathways, access to biomarker testing, clinical trial access, and transparency in drug approval and public funding.
01
Patients and families should have a clearer route through diagnosis, treatment, and supportive care.
We advocate for nationally coordinated recommendations and practical care pathways, backed by implementation and accountability.
Explore national care pathways →02
Patients should have timely access to appropriate testing and help understanding what the results mean.
We advocate for clear testing pathways, equitable public funding, and results that can inform treatment and clinical-trial discussions.
Explore biomarker testing access →03
Geography and financial circumstances should not create avoidable barriers to being considered for research participation.
We advocate for clearer referral pathways, support with participation costs, and opportunities to participate closer to home where appropriate.
Explore clinical trial access →04
Patients should be able to understand where a treatment stands, who is responsible for the next decision, and what that decision means for access.
We advocate for a clearer, connected public record of regulatory reviews, reimbursement assessments, price negotiations, and funding decisions.
Explore drug approval transparency →Care pathways establish clearer expectations for care. Biomarker testing can help inform some treatment and trial decisions — though it does not always produce a treatment change or a trial option. Better trial access helps people explore appropriate research opportunities.
Running across all of it is transparency: at each step, patients should be able to see where a treatment or decision stands. These are connected parts of care, not a sequence every patient follows. Our focus is not simply on publishing recommendations, but on whether patients can access the services those recommendations describe.
We advance these priorities through policy development, research, collaboration, and public reporting.
In development
Christopher Cutler serves on the working committee developing national pancreatic cancer care pathways alongside Craig's Cause Pancreatic Cancer Society — the work behind our first priority.
Our care pathways priority →Published
Our Policy Builders of Tomorrow national audit and provincial report card examined testing access, trial access, drug coverage, and wait times in every province — the evidence base under all four priorities.
See the report card →Submitted
Our Budget 2026 pre-budget submission put costed asks to the federal government — including $50 million over five years for pan-Canadian biomarker testing equity.
Reports & submissions →Our evidence
Explore our pancreatic cancer report card and the evidence behind its findings.
View the report card →This page explains our policy agenda. Our patient resources explain testing, treatment, clinical trials, and practical support.
Explore patient resources →